What this study adds
Pirfenidone and nintedanib dose-dependently attenuated severe silicosis, mainly via regulating immune response and metabolic abnormalities. The low-dose combined-therapy outperformed monotherapy on fibrosis remission, potentially via synergic mechanisms indicated by multi-omics.